NEWS
Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the European Association of Cancer Research’s EACR 2021 Congress, which will take place from June 9 -12
Tollys earns ‘Best-in-class therapeutic innovation’ award from MATWIN for its drug candidate TL-532
Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase.
Tollys appoints Amina Zinaï, MD, as head of clinical development
Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.
Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
Professor Jean-Yves Blay, current member of the scientific advisory board, takes up chairmanship as company prepares to launch clinical programs.
Tollys appoints Philippe Goupit as chairman of the board
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Tollys extends its executive management team with appointment of Bettina Werle as CSO
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Tollys receives over €1.5 million deep tech financing from Bpifrance
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Tollys closes pre-Series A financing of €2.3 million
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE